Immune Niche Formation Reveals Mechanisms of Tumor Dormancy and Targeting Opportunities

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Residual tumor cells can persist in a dormant state for decades, with unclear mechanisms governing growth control and metastasis.
• Understanding tumor dormancy is crucial for developing effective cancer therapies and overcoming treatment resistance.

Purpose of the Study:

• To elucidate the molecular mechanisms driving tumor dormancy.
• To identify novel therapeutic targets for eradicating dormant tumor cells and overcoming resistance to immune checkpoint blockade (ICB).

Main Methods:

• Investigated the role of myeloid TGF-β RII abrogation in creating an IFN-γ-rich microenvironment.
• Analyzed KLF4-mediated SLURP1 production and its role in malignant cell quiescence via fibronectin-integrin pathways.
• Characterized immune cell composition within dormant tumor lesions and identified the CD200-CD200R1 axis in immune surveillance inactivation.
• Evaluated combination therapy involving targeting the CD200-mediated niche, chemotherapy, and ICB.

Main Results:

• Abrogation of myeloid TGF-β RII led to an IFN-γ-rich microenvironment.
• IFN-γ induced KLF4-mediated SLURP1 production, crucial for tumor cell quiescence by disrupting fibronectin-integrin signaling.
• Dormant lesions were located in immune niches rich in NK cells, cDCs, monocytes, and neutrophils.
• Tumor cells inactivated NK cell surveillance via CD200-CD200R1, contributing to dormancy.
• Targeting the CD200-mediated niche combined with chemotherapy and ICB eradicated dormant tumor cells.

Conclusions:

• The IFN-γ-KLF4-SLURP1 and CD200-CD200R1 axes are key regulators of tumor dormancy through immune-tumor crosstalk.
• Targeting the CD200-mediated dormant niche offers a promising strategy for eradicating dormant tumor cells and overcoming ICB resistance.